Allison Martin

5.1k total citations · 1 hit paper
73 papers, 2.4k citations indexed

About

Allison Martin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Allison Martin has authored 73 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 18 papers in Immunology. Recurrent topics in Allison Martin's work include Cancer Immunotherapy and Biomarkers (25 papers), Renal cell carcinoma treatment (19 papers) and Brain Metastases and Treatment (11 papers). Allison Martin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (25 papers), Renal cell carcinoma treatment (19 papers) and Brain Metastases and Treatment (11 papers). Allison Martin collaborates with scholars based in United States, United Kingdom and India. Allison Martin's co-authors include Ayal A. Aizer, Daniel Cagney, Paul J. Catalano, Brian M. Alexander, Amanda J. Redig, Daphne A. Haas‐Kogan, Eudocia Q. Lee, Patrick Y. Wen, Nancy U. Lin and Roberto Bellucci and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Allison Martin

68 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study

2017 500 citations Daniel Cagney, Allison Martin et al. profile →

Peers

Allison Martin

ONCOL

PRM

GENET

IMMUN

April F. Eichler United States

Sophie Camilleri‐Broët France

Zachary S. Buchwald United States

Akos Czibere United States

Robert Ilaria United States

Élodie Vauléon France

Radek Lakomý Czechia

Isabell Witzel Germany

Melinda S. Merchant United States

Anna Maria Di Giacomo Italy

April F. Eichler United States

Allison Martin

1.1k ×0.8

ONCOL

1.2k ×0.9

PRM

1.0k ×1.7

GENET

689 ×1.3

194 ×0.4

IMMUN

Citations per year, relative to Allison Martin Allison Martin (= 1×) peers April F. Eichler

Countries citing papers authored by Allison Martin

Since Specialization

Citations

This map shows the geographic impact of Allison Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison Martin more than expected).

Fields of papers citing papers by Allison Martin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allison Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison Martin. The network helps show where Allison Martin may publish in the future.

Co-authorship network of co-authors of Allison Martin

This figure shows the co-authorship network connecting the top 25 collaborators of Allison Martin. A scholar is included among the top collaborators of Allison Martin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allison Martin. Allison Martin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tabrizian, Parissa, Julio R. Gutiérrez, Maarouf Hoteit, et al.. (2025). Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study. Hepatology. 82(3). 612–625. 3 indexed citations

Tanwar, Ankit, et al.. (2025). The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics. Trends in Pharmacological Sciences. 46(10). 975–988.

Galbo, Phillip M., Joanne Xiu, Soma Sengupta, et al.. (2024). VISTA Emerges as a Promising Target against Immune Evasion Mechanisms in Medulloblastoma. Cancers. 16(15). 2629–2629. 4 indexed citations

Ornstein, Moshe Chaim, Wei Wei, C. Marcela Díaz‐Montero, et al.. (2024). Phase II Trial of Intermittent Therapy in Patients with Metastatic Renal Cell Carcinoma Treated with Front-line Ipilimumab and Nivolumab. Clinical Genitourinary Cancer. 22(6). 102181–102181.

Schuster, James, C.A. Reddy, Alok A. Khorana, et al.. (2023). Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 22(2). 92–97. 1 indexed citations

Nizam, Amanda, Ryan K. Rader, Alice Tzeng, et al.. (2023). Safety and Efficacy Outcomes in Immune Checkpoint Inhibitor-Treated Patients With Metastatic Urothelial Carcinoma Requiring Treatment Interruption or Discontinuation Due to Immune-Related Adverse Events. Clinical Genitourinary Cancer. 22(2). 368–379. 6 indexed citations

Wee, Christopher Eing, Amanda Nizam, Moshe Chaim Ornstein, et al.. (2023). Using sacituzumab govitecan for metastatic urothelial carcinoma after prior treatment with enfortumab vedotin: A single institution experience.. JCO Global Oncology. 9(Supplement_1). 78–78. 2 indexed citations

Jung, Geena, Timothy Kim, Mandana Behbahani, et al.. (2023). A Case Report of Infant-Type Hemispheric Glioma with a Novel GAB1-ABL2 Kinase Fusion Treated with Dasatinib. Pediatric Neurosurgery. 59(1). 27–34. 2 indexed citations

Ornstein, Moshe Chaim, Laura S. Wood, Brian P. Hobbs, et al.. (2019). A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy. Journal for ImmunoTherapy of Cancer. 7(1). 127–127. 24 indexed citations

10.

Ornstein, Moshe Chaim, Cassandra Calabrese, Laura S. Wood, et al.. (2019). Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer. 17(3). 177–182. 9 indexed citations

11.

Cagney, Daniel, Nayan Lamba, Allison Martin, et al.. (2019). Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases. Breast Cancer Research and Treatment. 176(1). 171–179. 18 indexed citations

12.

Ornstein, Moshe Chaim, Sumanta K. Pal, Laura S. Wood, et al.. (2019). Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. The Lancet Oncology. 20(10). 1386–1394. 78 indexed citations

13.

Ruble, Kathy, E. Juliana Paré‐Blagoev, Stacy Cooper, Allison Martin, & Lisa A. Jacobson. (2018). Parent perspectives on oncology team communication regarding neurocognitive impacts of cancer therapy and school reentry. Pediatric Blood & Cancer. 66(1). e27427–e27427. 27 indexed citations

14.

Cagney, Daniel, Allison Martin, Paul J. Catalano, et al.. (2018). Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiotherapy and Oncology. 126(3). 511–518. 17 indexed citations

15.

Tantravedi, Saritha, Farhad Vesuna, Paul T. Winnard, et al.. (2018). Targeting DDX3 in Medulloblastoma Using the Small Molecule Inhibitor RK-33. Translational Oncology. 12(1). 96–105. 37 indexed citations

16.

Lamba, Nayan, Daniel Cagney, Allison Martin, et al.. (2018). Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. World Neurosurgery. 122. e1557–e1561. 19 indexed citations

17.

Martin, Allison, Daniel Cagney, Paul J. Catalano, et al.. (2017). Brain Metastases in Newly Diagnosed Breast Cancer. JAMA Oncology. 3(8). 1069–1069. 228 indexed citations

18.

Bellucci, Roberto, Allison Martin, Davide Bommarito, et al.. (2015). Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. OncoImmunology. 4(6). e1008824–e1008824. 255 indexed citations

19.

Martin, Allison, Thomas R. Nirschl, Christopher J. Nirschl, et al.. (2015). Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer and Prostatic Diseases. 18(4). 325–332. 142 indexed citations

20.

Bellucci, Roberto, Allison Martin, Stefan Heinrichs, et al.. (2012). Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. Journal of Clinical Investigation. 122(7). 2369–2383. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact